|

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

RECRUITINGSponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
SponsorAssistance Publique - Hôpitaux de Paris
Started2025-11-03
Est. completion2029-11-02
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07010250

Summary

The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with an indication for initial diagnostic PBR on native kidney
* 18 ans ≥ Age ≤ 90 ans
* Affiliation to french health insurance
* Patient having given consent

For the ANCA vasculitis group:

• Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO)

For the control groups:

• Diagnosis retained after the renal biopsy

* Interstitial Nephritis
* Or glomerular nephropathy such as minimal change nephropathy
* Or Segmental hyalinosis in itscollapsing form
* Or Extramembranous Glomerulopathy,
* Or glomerulopathy with mesangial IgA deposits
* Or diabetic nephropathy.

Exclusion Criteria:

* Kidney transplant patient
* Patient on dialysis (hemodialysis or peritoneal dialysis)
* Patient under legal protection, guardianship or curatorship
* Pregnancy or breastfeeding
* Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.

Conditions8

ANCA Associated VasculitisDiabetesDiabetic NephropathiesExtramembranous GlomerulopathyIgA NephropathyInterstitial NephritisNephrotic Syndrome, Minimal ChangeSegmental Hyalinosis

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.